The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.
The Isentress (raltegravir) and Isentrress (raltegravir) HD label was recently updated to include Week 96 data from the Phase 3 trial (ONCEMRK).
The Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including Heplisav-B on its list of ACIP recommended products.
The updated guidelines include new definitions of disease phases, expanded indications for initiating treatment and recommendations for special populations.
The Food and Drug Administration (FDA) has approved Vemlidy (tenofovir alafenamide [TAF]) for the treatment of adults with hepatitis B virus (HBV) infection with compensated liver disease.